Evidence map›Paper›PMID 36312982›Full record

ArticleFrontiers in microbiology2022

Systematic benchmarking of nanopore Q20+ kit in SARS-CoV-2 whole genome sequencing.

Junhong Luo, Zixinrong Meng, Xingyu Xu, Lei Wang, Kangchen Zhao, Xiaojuan Zhu, Qiao Qiao, Yiyue Ge, Lingfeng Mao, Lunbiao Cui

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Nanopore Data-Driven T2T Genome Assemblies ofJournal of fungi (Basel, Switzerland) · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Junhong LuoSchool of Public Health, Nanjing Medical University, Nanjing, China.
Zixinrong MengSchool of Public Health, Nanjing Medical University, Nanjing, China.
Xingyu XuHangzhou Baiyi Technology Co., Ltd., Hangzhou, China.
Lei WangHangzhou Baiyi Technology Co., Ltd., Hangzhou, China.
Kangchen ZhaoNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Province Engineering Research Center of Health Emergency, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Xiaojuan ZhuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Province Engineering Research Center of Health Emergency, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Qiao QiaoNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Province Engineering Research Center of Health Emergency, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Yiyue GeNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Province Engineering Research Center of Health Emergency, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Lingfeng MaoHangzhou Baiyi Technology Co., Ltd., Hangzhou, China.
Lunbiao CuiSchool of Public Health, Nanjing Medical University, Nanjing, China.
Jiangsu Provincial Center for Disease Control and Prevention · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whole genome sequencing provides rapid insight into key information about the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), such as virus typing and key mutation site, and this information is important for precise prevention, control and tracing of coronavirus disease 2019 (COVID-19) outbreak in conjunction with the epidemiological information of the case. Nanopore sequencing is widely used around the world for its short sample-to-result time, simple experimental operation and long sequencing reads. However, because nanopore sequencing is a relatively new sequencing technology, many researchers still have doubts about its accuracy. The combination of the newly launched nanopore sequencing Q20+ kit (LSK112) and flow cell R10.4 is a qualitative improvement over the accuracy of the previous kits. In this study, we firstly used LSK112 kit with flow cell R10.4 to sequence the SARS-CoV-2 whole genome, and summarized the sequencing results of the combination of LSK112 kit and flow cell R10.4 for the 1200bp amplicons of SARS-CoV-2. We found that the proportion of sequences with an accuracy of more than 99% reached 30.1%, and the average sequence accuracy reached 98.34%, while the results of the original combination of LSK109 kit and flow cell R9.4.1 were 0.61% and 96.52%, respectively. The mutation site analysis showed that it was completely consistent with the final consensus sequence of next generation sequencing (NGS). The results showed that the combination of LSK112 kit and flow cell R10.4 allowed rapid whole-genome sequencing of SARS-CoV-2 without the need for verification of NGS.

Indexed as

accuracycoronavirusnanopore sequencingQ20+ kitSARS-CoV-2

Identifiers

PMID36312982
PMCPMC9612837
OpenAlexW4304845571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.